Selective downregulation of the MDR1 gene product in Caco-2 cells by stable transfection to prove its relevance in secretory drug transport

Molecular Pharmaceutics

Volumn 2, Issue 1, 2005, Pages 64-73

  Hilgendorf, Constanze ^a,b   Spahn Langguth, Hilde ^a   Rhedin, Magdalena ^b   Regårdh, Carl Gunnar ^b   Lo̊wenadler, Bjo̊rn ^b   Langguth, Peter ^b,c  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b ASTRAZENECA   (United Kingdom)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Caco 2 cells; Drug absorption; Drug transport; MDR1 transfection; P glycoprotein; P gp antisense DNA; Talinolol

Indexed keywords

COMPLEMENTARY DNA; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; OLIGONUCLEOTIDE; TALINOLOL;

ARTICLE; CANCER CHEMOTHERAPY; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG RESISTANCE; DRUG TRANSPORT; ELECTROPORATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE CONTROL; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTESTINE CELL; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; CLONE CELLS; DOWN-REGULATION; FLOW CYTOMETRY; GENES, MDR; HUMANS; MUTAGENESIS, INSERTIONAL; P-GLYCOPROTEINS; PERMEABILITY; PROPANOLAMINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TRANSFECTION; VERAPAMIL;

EID: 14644402404     PISSN: 15438384     EISSN: None     Source Type: Journal    
DOI: 10.1021/mp049931y     Document Type: Article

References (35)

1. Jaroszewski; J. W.; Kaplan, O.; Syi, J.-L.; Schested, M.; Faustino, P. J.; Cohen, J. S. Concerning antisense inhibition of the multiple drug resistance gene. Cancer Commun. 1990, 2, 287-294.
2. Morgan, P. P. New hope for overcoming acquired drug resistance. Can. Med. Assoc. J. 1993, 148, 1713-1716.
3. Fricker, G.; Drewe, J.; Huwyler, J.; Gutmann, H.; Beglinger, C. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br. J. Pharmacol. 1996, 118, 1841-1847.
4. Saitoh, H.; Aungst, B. J. Possible involvement of multiple p-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm. Res. 1995, 12, 1304-1310.
5. Plumb, J. A.; Milroy, R.; Kaye, S. B. The activity of verapamil as a resistance modifier in vitro in drug resistant human tumor cell lines is not stereospecific. Biochem. Pharmacol, 1990, 39, 787-792.
6. Zhi, L.; L'Heureux, F.; Pouliot, J.-F.; Heckel, A.; Bamberger, U.; Georges, E. BIBW22 BS, a potent multidrug resistance-reversing agent, binds directly to P-gp and accumulates in drug-resistant cells. Mol. Pharmacol. 50, 482-492.
7. Archinal-Mattheis, A.; Rzepka, R. W.; Watanabe, T.; Kokubu, N.; Itoh, Y.; Combates, N. J.; Bair, K. W.; Cohen, D. Analysis of the interactions of SDZ PSC833 ([3′-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol. Res. 1995, 7, 603-610.
8. Hofmann, J.; Wolf, A.; Spitaler, M.; Böck, G.; Drach, J.; Ludescher, C.; Grunicke, H. Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine. J. Cancer Res. Clin. Oncol. 1992, 118, 361-366.
9. Lush, R. M.; Meadows, B.; Fojo, A. T.; Kalafsky, G.; Smith, H. T.; Bates, S.; Figg, W. D. Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. J. Clin. Pharmacol. 1997, 37, 123-128.
10. Beck, G. F.; Irwin, W. J.; Nicklin, P. L.; Akhtar, S. Interactions of Phosphodiester and Phosphorothioate Oligonucleotides with Intestinal Epithelial Caco-2 Cells. Pharm. Res. 1996, 13, 1028-1037.
11. Sola, J. E.; Colombani, P. M. Modulation of multidrug resistance with antisense oligodesoxynucleotide to mdr1 mRNA. Ann. Surg. Oncol. 1996, 3, 80-85.
12. Nakashima, E.; Matsushita, R.; Negishi, H.; Nomura, M.; Harada, S.-I.; Yamamoto, H.; Miyamoto, K.-I.; Ichimura, F. Reversal of drug sensitivity in MDR subline of P388 leukemia by gene-targeted antisense-oligonucleotide. J. Pharm. Sci. 1995, 84, 1205-1209.
13. Corrias, M. V.; Tonini, G. P. An oligomer complementary to the 5′ end region of MDR1 gene decreases resistance to doxorubicin of human adenocarcinoma-resistant cells. Anticancer Res. 1992, 72, 1431-1438.
14. Holm, P. S.; Scanlon, K. J.; Dietel, M. Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br. J. Cancer 1994, 70 (2), 239-243.
15. Wetterich, U.; Spahn-Langguth, H.; Mutschler, E.; Terhaag, B.; Rösch, W.; Langguth, P. Evidence for intestinal secretion as an additional clearance pathway of Talinolol enantiomers: concentration- and dose-dependent absorption in-vitro and in-vivo. Pharm. Res. 1996, 13, 514-522.
16. Hunter, J.; Hirst, B. H. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv. Drug Delivery Rev. 1997, 25, 129-158.
17. Terao, T.; Hisanaga, E.; Sai, Y.; Tamai, I.; Tsuji, A. Active secretion of drugs from the small intestinal epithelium of rats by p-glycoprotein functioning as an absorption barrier. J. Pharm. Pharmacol. 1996, 48, 1083-1089.
18. Hillgren, K. M.; Kato, A.; Borchardt, R. T. In vitro systems for studying intestinal drug absorption. Med. Res. Rev. 1995, 75, 83-109.
19. Hidalgo, I. J.; Raub, T. J.; Borchardt, R. T. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989, 96, 736-749.
20. Hunter, J.; Jepson, M. A.; Tsuruo, T.; Simmons, N. L.; Hirst, B. H. Functional expression of P-glycoprotein in apical membrane of human intestinal Caco-2 cells. J. Biol. Chem. 1993, 268, 14991-14997.
21. Adachi, Y.; Suzuki, H.; Sugiyama, Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm. Res. 2001, 18, 1660-1668.
22. Seithel, A.; Karlsson, J.; Hilgendorf, C.; Björquist, A.; Ungell, A. L. Variability in gene expression of drug transporters by age and passage in Caco-2 cells. Presented at the EUFEPS Conference on Drug Transporters, Copenhagen, April 19-21, 2004; paper PO-12.
23. Kostenko, E. V.; Laktionov, P. P.; Vlassov, V. V.; Zenkova, M. A. Downregulation of PGY1/MDR1 mRNA level in human KB cells by antisense oligonucleotide conjugates. RNA accessibility in vitro and intracellular antisense activity. Biochim. Biophys. Acta 2002, 1576 (1-2), 143-147.
24. Lincke, C. R.; van der Bliek, A. M.; Schuurhuis, G. J.; van der Velde-Korts, T.; Smit, J. J.; Borst, P. Multidrug resistance phenotype of humanBRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. Cancer Res. 1990, 50, 1779-1785.
25. Ausubel, F. M.; Bront, R.; Kingston, R. E.; Moore, D. D.; Seldmann, J. G.; Smith, J. A.; Struhl, K. Current protocols in molecular biology on CD-ROM; John Wiley & Sons Inc.: New York, 1997.
26. Southern, P. J.; Berg, P. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under the control of the SV40 early region promoter. J. Mol. Appl. Genet. 1982, 1, 327-331.
27. Anderle, P.; Niederer, E.; Kubas, W.; Hilgendorf, C.; Spahn-Langgguth, H.; Wunderli-Allenspach, H.; Merkle, H.-P.; Langguth, P. P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: The influence of culturing conditions and drug exposure on P-gp expression levels. J. Pharm. Sci. 1998, 87, 757-762.
28. Wetterich U. Bioanalytical and pharmacokinetic studies on the β-adrenoceptor antagonizing talinolol. Ph.D. Thesis, School of Pharmacy, Johan Wolfgang Goethe University Frankfurt/Main, 1995.
29. Hilgendorf, C. The intestinal epithelial barrier in vitro: Carrier-mediated and passive transport in normal and genetically modified Caco-2 cells and other intestinal cell lines. Ph.D. Thesis, School of Pharmacy, Martin Luther University Halle-Wittenberg, Halle/Saale, 1999.
30. Döppenschmitt, S.; Spahn-Langguth, H.; Regardh, C. G.; Langguth, P. Radioligand binding assay employing P-gp overexpressing cells: Testing drug affinities to the secretory intestinal multidrug transporter. Pharm. Res. 1998, 16, 1067-1072.
31. Woolf, T. M.; Jennings, C. G. P.; Rebagliati, M.; Melton, D. The stability, toxicity and effectiveness of unmodified and phosphothioate antisense oligodeoxynucleotides in Xenopus oocytes and embryos. Nucleic Acids Res. 1990, 18, 1763-1769.
32. Woodcock, S.; Williamson, I.; Hassan, I.; Mackay, M. Isolation and characterization of clones from the Caco-2 cell line displaying increased taurocholic acid transport. J. Cell Sci. 1991, 98, 323-332.
33. Spahn-Langguth, H.; Baktir, G.; Radschuweit, A.; Okyar, A.; Terhaag, B.; Ader, P.; Hanafy, A.; Langguth, P. P-Glycoprotein transporters and the gastrointestinal tract; Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. 1998, 36, 16-24.
34. Leisen, C.; Langguth, P.; Herber, B.; Dressler, C.; Koggel, A.; Spahn-Langguth, H. Lipophilicities of baclofen ester prodrugs correlate with affinities to the ATP-dependent efflux pump P-glycoprotein: Relevance for their permeation across the blood-brain barrier? Pharm. Res. 2003, 20, 772-778.
35. Tang, F.; Horie, K.; Borchardt, R. T. Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm. Res. 2002, 19, 773-779.